Stevanato Group S.p.a. · NYSE:STVN
Stevanato — Q4 2024 Earnings Presentation
22 slides from Stevanato's earnings presentation, Mar 6, 2025
Slide 1: Stevanato Group Q4 and FY 2024 Financial Results
Stevanato Group Q4 and FY 2024 Financial Results March 6, 2025
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”) a
Slide 3: Q4 and Full Year 2024 Financial Results Earnings Call
Stevanato Group Q4 and Full Year 2024 Financial Results Earnings Call Franco Marco Lisa Stevanato Dal Lago Miles Chairman & CEO CFO IR Q4 and FY 2024 Financial Results 3
Slide 4: Franco Stevanato
x Franco Stevanato Chairman & Chief Executive Officer Q4 and FY 2024 Financial Results
Slide 5: Finished 2024 with Positive Fourth Quarter Results
Finished 2024 with Positive Fourth Quarter Results • FY 2024 revenue grew 2% yoy, driven by 6% BDS Segment growth that offset the expected decline from Engineering Segment • 2024 growth was fueled primarily by a 15% increase in HVS, representing 38% of total revenue for FY 2024 → HVS success indicat
Slide 6: Demand-Driven Capacity Expansion Update
Demand-Driven Capacity Expansion Update Fishers (IN), U.S. Latina, Italy Supporting U.S. customers across the full value chain, Diversifying EMEA footprint with expanding capacity strategically focused to meet high demand for biologics for PFS and EZ-fill cartridge to satisfy market demand • Commerc
Slide 7: Engineering Optimization Plan
Engineering Optimization Plan Plan aimed at improving both short- and long-term performance of the Segment Major strides during the quarter and on track to complete The next phase of our plan has a longer horizon, and we will the previously delayed projects in 2025 be focused on right-sizing the ove
Slide 8: Positioned to Drive Long-Term Sustainable Growth
Positioned to Drive Long-Term Sustainable Growth Challenges in 2024 prompted us to take actions to Took actions in 2024 aimed to: Uniquely positioned with an integrated value proposition • Improve execution • Drive operational improvements through footprint History of embedding science and technolog
Slide 9: Marco Dal Lago
x Marco Dal Lago Chief Financial Officer Q4 and FY 2024 Financial Results
Slide 10: Q4 2024: Financial Highlights
Q4 2024: Financial Highlights Q4 2024 : Revenue Q4 2024: Margins (€ Million) HVS non-HVS • Gross profit margin decreased 210 bps to 29.7% +3% • (i) Strong mix of HVS and (ii) year-over-year improvement in 321 331 Fishers and Latina partially offset the temporary unfavorable impacts from: 201 200 − V
Slide 11: Q4 2024: Segment Trends
Q4 2024: Segment Trends Biopharmaceutical and Diagnostic Solutions Segment (BDS) REVENUE Q4 2024 revenue increased 7% (8% at cc), driven by HVS syringes and other products 260 279 (€ Million) • Growth offset by 14% revenue decline in vials (more pronounced in EZ-fill® vials) Q4 2023 Q4 2024 • Revenu
Slide 12: Balance Sheet and Cash Flow Items
Balance Sheet and Cash Flow Items At Quarter Ended December 31, 2024 € 98.3M € 335M Total Cash and Cash Net Debt* Equivalents In Fiscal Year 2024 € 286.6M € 155.8M (€ 148.5M) CapEx* Net Cash Generated Free Cash Flow* from Operations __________ *Net Debt, CapEx, Free Cash Flow are non-GAAP financial
Slide 13: FY 2025 Guidance
FY 2025 Guidance FY 2025 Guidance Revenue € 1.160B - € 1.190B Implied Revenue Growth 5% to 8% Adjusted DEPS* € 0.51 - € 0.55 Adjusted EBITDA* € 293.0M - € 306.3M FY 2025 Guidance assumes: • The second half of 2025 will be stronger than the first half | Consistent with prior years, revenue step down
Slide 14: Franco Stevanato
x Franco Stevanato Chairman & Chief Executive Officer Q4 and FY 2024 Financial Results
Slide 15: Fundamentals Remain Strong with Favorable Secular Tailwinds
Fundamentals Remain Strong with Favorable Secular Tailwinds Focused on executing our key priorities. Several reasons to be confident in our strategic direction: 1. Continue to deliver organic growth, primarily driven by HVS, indicating we are investing in the right areas to meet growing demand 2. Ex
Slide 16: Thank You
Stevanato Group Q4 and FY 2024 Financial Results Thank You
Slide 17: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non-GAAP measures. Management monitors and evaluates our operating and financial performance using several non-GAAP f
Slide 18: Reconciliation of Non-GAAP Financial Measures (1/5)
Reconciliation of Non-GAAP Financial Measures (1/5) Reconciliation of Revenue to Constant Currency Revenue Reconciliation of EBITDA (Amounts in € millions) (Amounts in € millions) Biopharmaceutical For the three months For the years and Change Change ended December 31, ended December 31, Diagnostic
Slide 19: Reconciliation of Non-GAAP Financial Measures (2/5)
Reconciliation of Non-GAAP Financial Measures (2/5) Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit, and Diluted EPS (Amounts in € millions, except per share data) Three months ended December 31, Operating Income Operating Income EBITDA Net Profit Diluted E
Slide 20: Reconciliation of Non-GAAP Financial Measures (3/5)
Reconciliation of Non-GAAP Financial Measures (3/5) Capital Employed (Amounts in € millions) As of As of December 31, December 31, 2024 2023 - Goodwill and Other intangible assets 83.6 81.0 - Right of Use assets 15.7 18.2 - Property, plant and equipment 1,248.4 1,028.5 - Financial assets - investmen
Slide 21: Reconciliation of Non-GAAP Financial Measures (4/5)
Reconciliation of Non-GAAP Financial Measures (4/5) CAPEX Net (Debt) / Net Cash (Amounts in € millions) (Amounts in € millions) For the three months Change For the year Change As of December 31, As of December 31, ended December 31, ended December 31, 2024 2023 2024 2023 € 2024 2023 € Non-current fi
Slide 22: Reconciliation of Non-GAAP Financial Measures (5/5)
Reconciliation of Non-GAAP Financial Measures (5/5) Reconciliation of 2025 Guidance* Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS (Amounts in € millions, except per share data) Operating Revenue EBITDA Net Profit Diluted EPS Profit * 1,160-0- Reported 1,190.0 284.8-298.1 1